Physician profile
Donna Ignacio Vasquez
NPI 1154333169
$498.89
in general payments reported to CMS, 2019-2025
15 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.55 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.27 | 2025 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $53.98 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $46.97 | 2025 | Rexulti |
| Antares Pharma, INC. | $46.95 | 2025 | Xyosted |
| Novo Nordisk INC | $41.50 | 2025 | Wegovy |
| Abbott Laboratories | $40.58 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $34.87 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $32.85 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $31.88 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $31.54 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $22.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.16 | 2020 | |
| Cipher Pharmaceuticals US LLC | $14.94 | 2025 | Spinosad, Natroba |
| Amgen INC. | $14.61 | 2025 | Krystexxa |
| Exact Sciences Corporation | $14.42 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.